Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy.

@article{Chernin2012SecondaryPO,
  title={Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy.},
  author={Gil Chernin and Amir Gal-Oz and Eyal Ben-Assa and Idit Feenberg Schwartz and T Weinstein and Doron Schwartz and Donald S. Silverberg},
  journal={Clinical cardiology},
  year={2012},
  volume={35 1},
  pages={32-6}
}
BACKGROUND Hyperkalemia, induced by renin-angiotensin-aldosterone system inhibition (RAAS-I) in patients with chronic kidney disease (CKD), or cardiac disease often leads to withdrawal of RAAS-I therapy. Sodium polystyrene sulfonate (SPS) is a potassium-binding resin used for the treatment of hyperkalemia. Recently, concerns about the safety and efficacy of SPS were raised. We report here a follow-up of 14 patients with CKD and heart disease on RAAS-I treatment who were treated with low-dose… CONTINUE READING
21 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

531–548

  • Rolfe M. Potassium homeostasis Weir MR, renin-angiotensinaldosterone system inhibitors. Clin J Am Soc Nephrol. 2010
  • 36 Clin. Cardiol. 35, 1, 32–36
  • 2012

Similar Papers

Loading similar papers…